Plain-English translation of NCT07283770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing a new medication called , which is being developed to treat cystic fibrosis. Researchers want to understand how safe the medication is and how the body absorbs, processes, and eliminates it. The study will test the medication at increasing doses — first giving participants a single dose, then later giving multiple doses over time.
Before any new medication can be given to patients with a disease, it must first be tested in healthy people to ensure it is safe and to understand how the body handles it. This early testing helps researchers decide if this treatment should move forward to be tested in patients with cystic fibrosis.
You likely qualify if…
You likely don't qualify if…
You will go through a screening phase to confirm you are healthy, then enter the treatment phase where you will receive either the medication or a placebo (a fake pill). Some participants will receive a single dose, while others will receive multiple doses over several days or weeks. After the treatment phase, you will be monitored during a follow-up period to track how you respond and ensure your safety.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment target
~136 participants
Started
December 2025
Primary completion
November 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Medical Information
Vertex Pharmaceuticals Incorporated
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.